Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

2012 • 16,041 citations

Standardisation of spirometry

2005 • 14,522 citations

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

2001 • 6,099 citations

Interpreting thresholds for a clinically significant change in health status in asthma and COPD

2002 • 565 citations

Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE study

2013 • 370 citations

Tiotropium and olodaterol fixed-dose combinationversusmono-components in COPD (GOLD 2–4)

2015 • 297 citations

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD

2013 • 249 citations

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials

2014 • 228 citations

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

2003 • 222 citations

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

2012 • 122 citations

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial

2014 • 115 citations

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

2014 • 91 citations

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

2014 • 70 citations

Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD

2010 • 57 citations

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies

2014 • 38 citations

The 24 Hour Lung Function Time Profile of Olodaterol Once Daily Versus Placebo and Tiotropium in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease

2014 • 28 citations

A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease

2015 • 16 citations

Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD

2012 • 11 citations

P258 The 24-hour Lung Function Profile Of Once-daily Tiotropium And Olodaterol Fixed-dose Combination Compared With Placebo And Monotherapies In Chronic Obstructive Pulmonary Disease

2014 • 7 citations